Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Lurbinectedin for the Treatment of Patients with Relapsed FET-Fused Tumors

Trial Status: active

This phase I/II tests the safety, side effects, effectiveness and best dose of lurbinectedin for the treatment of patients with FET-fused tumors that has come back after a period of improvement (relapsed). Chemotherapy drugs, such as lurbinectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.